NASDAQ · Biotechnology

ZBIO (ZBIO) Stock

$31.29 -3.55% NASDAQ: ZBIO Healthcare

Valuation

MetricValue
Price$31.29
Market Cap$1.98B
P/E Ratio-1.99
P/B Ratio3.09
P/S Ratio74.82
EPS (TTM)$-8.44
52-Week High$44.60
52-Week Low$8.91
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-156.20%
ROA-98.44%
ROCE-86.83%
Gross Margin-2110.00%
Operating Margin-2110.00%
Net Margin-3780.00%
Debt/Equity1.05
Current Ratio5.57

Annual Financials (USD)

Metric2022202320242025
Revenue$0$50.0M$5.0M$10.0M
Operating Profit$-76.0M$-37.0M$-164.0M$-211.0M
Net Profit$-119.0M$-37.0M$-157.0M$-378.0M
EPS$-3.11$-0.97$-3.76$-8.44
Op Margin—-74.3%-3277.8%-2113.8%

Balance Sheet (USD)

Metric2022202320242025
Total Assets$75.0M$68.0M$370.0M$384.0M
Total Liabilities$267.0M$294.0M$58.0M$141.0M
Cash$67.0M$57.0M$320.0M$111.0M
Borrowings$2.0M$21.0M$1.0M$80.0M

Latest News

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 17, 2026 Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says MT Newswires · Jul 17, 2026 Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential Insider Monkey · Jul 10, 2026 Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction. Motley Fool · Jun 21, 2026 Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit GlobeNewswire · Jun 11, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-66.0M$-31.0M$-120.0M$-172.0M
Investing Cash Flow$-4.0M$0$-31.0M$-252.0M
Financing Cash Flow$0$0$-6.0M$62.0M
Net Cash Flow$-8.0M$-10.0M$263.0M$-209.0M
Free Cash Flow$-68.0M$-31.0M$-120.0M$-172.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-27.88%
Quick Ratio11.94
Interest Coverage-30.14
Return 1Y98.40%
Return 3Y—
Return 5Y—

Ownership

Insiders Held18.29%
Institutions Held90.54%
Institutions Float Held110.81%
Institutional HolderSharesReport Date
FMR, LLC9,082,0002026-03-31
SR One Capital Management, LP5,037,8542026-03-31
NEA Management Company, LLC4,023,2192026-03-31
Enavate Sciences Gp, LLC 3,919,1592026-03-31
Federated Hermes, Inc.3,127,0312026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPL $310.03 +1.45% 37.72 $4.55T 0.34%
MSFT $481.63 +0.27% 22.95 $3.58T 0.94%
GOOGL $344.20 +0.06% 27.68 $4.17T 0.23%
AMZNAmazon.com, Inc. $253.71 +1.00% 20.14 $2.73T 0.00%
META $543.67 -4.45% 21.47 $1.38T 0.35%

About ZBIO

ZBIO is led by CEO Leon Oliver Moulder Jr., employs 130 people, headquartered in US, publicly traded since 2024.

ZBIO stock trades at $31.29 with a market capitalization of $1.98B. The stock is valued at a price-to-earnings (P/E) ratio of -1.99, price-to-book of 3.09, price-to-sales of 74.82. Over the past 52 weeks the stock has ranged between $8.91 and $44.60, and currently trades 29.8% below its 52-week high.

On profitability, ZBIO generates a return on equity (ROE) of -156.20%, return on capital employed of -86.83%, an operating margin of -2110.00%, a net profit margin of -3780.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1226.67 +3.68% JNJ Drug Manufacturers - General $271.11 +3.33% ABBV Drug Manufacturers - General $258.92 +3.43% UNH Medical - Healthcare Plans $393.93 -0.43% MRK Drug Manufacturers - General $135.18 -0.58% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $589.04 +0.60% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $27.25 +1.41%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides